Loading...
The integrase inhibitor raltegravir is a recommended option for initial HIV treatment, and a second integrase inhibitor, elvitegravir, is about to be approved as part of a new single-tablet regimen. Treatment responses to both drugs have been outstanding in clinical trials, but raltegravir requires twice-daily dosing and elvitegravir requires a pharmacologic booster to achieve therapeutic concentrations. A third integrase inhibitor, dolutegravir, addresses both of these limitations and has also shown excellent virologic efficacy — first compared with efavirenz in the SPRING-1 study (JW AIDS Clin Care May 7 2012) and now compared with raltegravir in the SPRING-2 study.
The SPRING-2 study, as described by Francois Raffi at the 2012 Internation…